Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Checkpoint inhibitors in breast cancer - current status
Anne Polk,
Inge-Marie Svane
, Michael Andersson,
Dorte Nielsen
Department of Clinical Medicine
55
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Checkpoint inhibitors in breast cancer - current status'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Triple-negative Breast Cancer
100%
Breast Cancer
100%
Embase
50%
Chemotherapy
50%
Tumor Immunity
50%
Immune Checkpoint Inhibitors
50%
Literature Search
50%
Neoadjuvant Setting
50%
Clinical Development
50%
Overall Response Rate
50%
Immune Checkpoint
50%
Computer-based
50%
Anticancer Agents
50%
Programmed Death-ligand 1 (PD-L1)
50%
Further Development
50%
Predictive Biomarker
50%
Multiple Trials
50%
PubMed
50%
Patient Selection
50%
Pathological Response
50%
Progression-free Survival
50%
International Meeting
50%
Overall Survival
50%
Monotherapy
50%
Breast Cancer Patients
50%
Treatment Modalities
50%
Number of Patients
50%
Medicine and Dentistry
Breast Cancer
100%
Biological Marker
66%
Triple Negative Breast Cancer
66%
Anticancer Drug
33%
Tumor Regression
33%
Monotherapy
33%
Standing
33%
Immunity
33%
Immune Checkpoint Inhibitor
33%
Overall Survival
33%
Progression Free Survival
33%
Programmed Death-Ligand 1
33%
Patient Selection
33%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Triple Negative Breast Cancer
66%
Biological Marker
66%
Tumor Regression
33%
Progression Free Survival
33%
Neoplasm
33%
Overall Survival
33%
Immune Checkpoint Inhibitor
33%
Monotherapy
33%
Anticancer Drug
33%
Chemotherapy
33%